Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
NCT ID: NCT00083434
Last Updated: 2011-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
INTERVENTIONAL
2004-02-29
2004-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
NCT00083486
Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy
NCT00270127
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
NCT00255749
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
NCT00003600
A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy
NCT00283465
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Epoetin alfa
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body weight \>/= 99lbs
* ECOG 0-2
* Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
* Screening hemoglobin level of \</= 11.0 g/dL for men or \</= 10.0 for women
Exclusion Criteria
* Evidence of primary or metastatic malignancy involving the Central Nervous System
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Advanced Urology Medical Center
Anaheim, California, United States
Shapiro, Stafford & Yee
Arcadia, California, United States
California Cancer Center
Fresno, California, United States
Tukoi Research
North Miami, Florida, United States
Hanover Medical Specialists, PA
Wilmington, North Carolina, United States
Madigan Army Medical Center Urology Services
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Approved Product labeling, refer to the following link:http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
Additional information is provided at the following link:http://dailymed.nlm.nih.gov/dailymed/about.cfm
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EPO-CAN-303
Identifier Type: -
Identifier Source: secondary_id
CR010549
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.